$31.730
+2.561 (+8.07%)Zum Schluss
QNCX im Vergleich zur Peergroup
In the context of the broader market, QNCX competes directly with industry leaders such as RNAZ and CVM. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, QNCX's gross margin of N/A stands against RNAZ's N/A and CVM's N/A. Such benchmarking helps identify whether IRulya Therapeutics Inc is trading at a premium or discount relative to its financial performance.
Finanzielle Entwicklung von Quince Therapeutics Inc
Quince Therapeutics has shown significant volatility in its financial performance, with a net income loss of $75,488,000 in Q2 2026. However, it posted a positive net income of $35,912,000 in Q1 2026, indicating potential recovery.
Financials
Ähnliche Artikel
- Equal-Weight vs Cap-Weighted S&P 500: RSP vs SPY After October's Rotation and Nvidia's CEO ShockEqual weight vs cap weighted S&P 500: how RSP and SPY differ, why October 2026's rotation was the widest since 2009, and how to blend both after Nvidia's shock.
- Money Market Funds vs High-Yield Savings vs T-Bills: Where to Park Cash as the Fed HikesMoney market funds, high-yield savings or T-bills? Compare November 2026 yields, taxes, FDIC rules and liquidity as the Fed hikes, and build a smart cash plan.
- Homebuilder Stocks With Mortgage Rates Above 7%: An Investor's Guide for Late 2026Homebuilder stocks face 7% mortgage rates and a 16-year low in home sales. See what D.R. Horton, Lennar and Pulte earnings show and how to invest in 2026.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.